During the last decade, moderate progress in the treatment of pancreatic ductal adenocarcinoma (PDAC) has been realized with updated chemotherapeutic regimens, advanced operative techniques, and in some cases, targeted genetic-based therapy. Treating patients with borderline resectable or locally advanced tumors using neoadjuvant chemotherapy may provide benefit.1 Current treatment regimens have extrapolated from the success of FOLFIRINOX (fluorouracil, leucovorin, irinotecan, and oxaliplatin) and gemcitabine plus nab-paclitaxel (GA) in the setting of metastatic PDAC.2,3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Ye L, Hines OJ. Should All Patients With Pancreatic Cancer Receive Chemotherapy Before Surgery? JAMA Surg. 2020;155(9):840. doi:10.1001/jamasurg.2020.2302
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: